Next date
None yet
Trials
1 active
13 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- Antihypoglycemic Agent FDA class
- How it’s given
- “Dasiglucagon, 0.6 mg/0.6 mL or 0.3 mg/0.3 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the buttocks.”In the company’s words, NCT05378672 on ClinicalTrials.gov
- Tested for
- Hypoglycemia (8 trials), Diabetes Mellitus, Type 1 (5 trials), Congenital Hyperinsulinism (3 trials), Type 1 Diabetes, Glucose Metabolism Disorders
- Main trialPhase 3
- “The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon\* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen. \*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207”In the company’s words, NCT03216226 on ClinicalTrials.gov
- Other names
- ZP4207 · Zegalogue
- Copy of
- Glucagen (Novo Nordisk)Tested side by side with the original in NCT03216226, NCT03378635, NCT03667053
Other drugs for Hypoglycemia
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 13 Feb 2018 | A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus | |
| Phase 3Completed | 27 Apr 2018 | A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects | |
| Phase 3Completed | 11 Mar 2019 | Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM | |
| Phase 3Completed | 28 Jun 2019 | Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children | |
| Phase 3Completed | 30 Jul 2019 | A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM | |
| Phase 3Completed | 31 Aug 2020 | A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism | |
| Phase 3Completed | 29 Oct 2024 | A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D | |
| Phase 3Completed | 28 Jan 2025 | Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism | |
| Phase 2/3Completed | 17 Feb 2022 | Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism | |
| Phase 2Completed | 24 May 2017 | Feasibility Trial Testing the Bionic Pancreas With ZP4207 | |
| Phase 2Withdrawn | Feb 2023 | Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults | |
| Phase 1Completed | 24 Jun 2019 | Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration | |
| Phase 4Authorised | not given | The POST-PRANDIAL HYPO-AVOID STUDY Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People with Type 1 Diabetes |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026